In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com. It is expected to increase in value by around 10.3% p/a to 2017, reaching $1.3 billion, on account of the anticipated US and European approval of Priligy (dapoxetine).
Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
The premature ejaculation medication market represents a distinct unmet treatment need, as there are very few therapies in development, and those that are in use tend to be off-label (i.e., prescribed for an unapproved indication), such as SSRIs.
Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment (and not in all countries).
Off-label drugs administered for the treatment of premature ejaculation include Prozac (fluoxetine), Zoloft (sertraline) and Paxil (paroxetine).
At present, physicians' preferred treatment for premature ejaculation is a behavioural method termed 'stop and squeeze', which yields satisfactory results and has no side effects.
It is estimated that the premature ejaculation market was valued at US$684 million in 2010, with the sector forecast to expand at 10.3% compound annual growth rate to 2017. By the end of 2017, the premature ejaculation market is forecast to be valued at US$1.3 billion. The expected approval of the branded drug Priligy (dapoxetine) and the prevalence of PE in the male population is expected to drive this growth.